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The inherited neurodegenerative disease Fried-
reich’s ataxia (FRDA) is caused by GAA,TTC triplet
repeat hyperexpansions within the first intron of the
FXN gene, encoding the mitochondrial protein
frataxin. Long GAA,TTC repeats cause heterochro-
matin-mediated gene silencing and loss of frataxin
in affected individuals. We report the derivation of
induced pluripotent stem cells (iPSCs) from FRDA
patient fibroblasts by transcription factor reprogram-
ming. FXN gene repression is maintained in the
iPSCs, as are the global gene expression signatures
reflecting the human disease. GAA,TTC repeats
uniquely in FXN in the iPSCs exhibit repeat instability
similar to patient families, where they expand and/or
contract with discrete changes in length between
generations. The mismatch repair enzyme MSH2,
implicated in repeat instability in other triplet repeat
diseases, is highly expressed in pluripotent cells
and occupies FXN intron 1, and shRNA silencing
of MSH2 impedes repeat expansion, providing
a possible molecular explanation for repeat expan-
sion in FRDA.
INTRODUCTION
Friedreich’s ataxia (FRDA), the most common inherited ataxia, is
caused by heterochromatin-mediated silencing of the nuclear
FXN gene, encoding the essential mitochondrial protein frataxin
(Herman et al., 2006). The genetic mutation in FRDA is
a GAA,TTC triplet-repeat expansion in the first intron of FXN
(Campuzano et al., 1996), with unaffected alleles having 6–34
repeats in contrast to 66–1700 repeats in patient alleles. Longer
repeats are associated with more severe gene repression, lower
frataxin protein levels, and earlier onset and increased disease
severity (Bidichandani et al., 1998; Campuzano et al., 1996).
Frataxin insufficiency leads to progressive spino-cerebellarCelneurodegeneration and associated movement disorders along
with an increased risk for diabetes and cardiomyopathy, the
latter being the most common cause of death in FRDA.
Unlike many triplet-repeat diseases (e.g., the polyglutamine
expansion and the RNA toxicity diseases) (Orr and Zoghbi,
2007), GAA,TTC expansions in FXN are intronic and do not alter
the frataxin protein sequence; thus, gene activation would be
of therapeutic benefit (Gottesfeld, 2007; Herman et al., 2006).
However, studies in FRDA pathogenesis and therapeutics are
limited by poor cellular models, and available mouse models
do not fully recapitulate gene silencing and frataxin protein levels
(Al-Mahdawi et al., 2004; Miranda et al., 2002). Recent studies
have shown that human fibroblasts can be reprogrammed to a
pluripotent state by transduction of transcription factors
(Takahashi et al., 2007), and importantly, the same has been
demonstrated with fibroblasts from repeat-associated neurode-
generative disease patients such as Huntington’s disease (HD)
and Fragile X syndrome (Park et al., 2008a; Urbach et al.,
2010). We now report the derivation of FRDA iPSCs. We find
that the FXN GAA,TTC repeats in FRDA iPSCs exhibit a repeat
instability pattern similar to the human disease, where repeats
expand and/or contract with discrete changes in length between
generations (Campuzano et al., 1996; Pianese et al., 1997). We
also provide evidence for the role of the mismatch repair
(MMR) enzyme MSH2 in repeat instability. Our observations
provide a cellular model system formechanistic studies of repeat
instability in FRDA and potentially other triplet repeat diseases.RESULTS
Derivation of iPSCs from FRDA Patient Fibroblasts
Primary fibroblasts from two FRDA patients (GM03816 and
GM04078 from the NIGMS Coriell Cell Repository) were reprog-
rammed by transcription factor overexpression (Takahashi et al.,
2007), and colonies with ESC/iPSC morphology were selected
and expanded (Figure 1A). Analysis by qRT-PCR shows that
our FRDA iPSC lines are indeed pluripotent (Figure 1B) and retain
marked repression of FXN mRNA (Figure 1C). Further, expres-
sion of the integrated transgenic reprogramming factors isl Stem Cell 7, 631–637, November 5, 2010 ª2010 Elsevier Inc. 631
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Figure 1. Characterization of FRDA iPSCs
(A) Images of GM03816 FRDA fibroblasts (left), GM03816 iPSCs (middle), and H1 hESCs (right). Scale bars represent 0.5 mm.
(B) GM03816-iPS4 shows similar expression of pluripotencymRNAs as H1 hESCs. GM03816 fibroblasts, white bars; GM03816 iPSCs, light gray; H1 hESCs, dark
gray. mRNA levels are normalized to GAPDH. Error bars indicate SEM of duplicate measurements.
(C) Hallmark repression of FXN mRNA in GM03816 fibroblasts and the GM03816-iPS4 line as compared to the unaffected H1 line. Error bars indicate SEM of
duplicate measurements.
(D) GM03816-iPS4 and H1 hESC staining (contrast enhanced) of pluripotency markers. Phase contrast (gray); nuclear staining (blue); pluripotency markers stain-
ing (green and red) is as denoted by the colored text labels. Tra1-60 and Tra1-81, surface markers; SSEA-3 and -4, stage-specific embryonic antigens; Oct4,
transcription factor. Scale bars represent 0.25 mm.
(E) Microarray analysis of FRDA iPSCs versus unaffected iPSC/ESCs, human tissues, and cell lines. Red represents upregulation, green represents downregu-
lation. Unaffected iPSC/ESCs, red highlighting; FRDA iPSCs, yellow; unaffected human tissue, blue; human cell lines, gray.
See also Figure S1 and Tables S1–S3.
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GAA,TTC Repeat Instability in FRDA iPSCssilenced in the iPSCs (Figure S1A available online), a hallmark of
full reprogramming (Lowry et al., 2008).
Immunostaining of FRDA iPSCs for pluripotent markers
(SSEA3 and SSEA4; Oct4; and Tra1-60 and Tra1-81) was also
found to be comparable to that of H1 ESCs (Figure 1D). Genotyp-
ing of the FXN gene GAA,TTC repeats and cytogenetic analysis
demonstrated that the iPSCs indeed originated from FRDA fibro-
blasts and are karyotypically normal (Figure 2A; Figure S1B), and
ChIP experiments confirm heterochromatin histone marks near
the FXN GAA,TTC repeats (Figures S1C–S1E; Al-Mahdawi
et al., 2008; Herman et al., 2006; Rai et al., 2008). Finally, tera-
toma analysis shows full in vivo differentiation capacity
(Figure S1F), providing additional evidence of the pluripotent
nature of the FRDA iPSCs.
Global mRNA Expression Profiles of FRDA iPSCs
Hierarchical clustering of global gene expression profiles of four
FRDA iPSC lines (two from GM03816, two from GM04078) with
a set of unaffected iPSCs, hESCs, and various human tissues
and cell lines show that our iPSC lines group to the same cluster632 Cell Stem Cell 7, 631–637, November 5, 2010 ª2010 Elsevier Incas other iPS/ESCs, though in a separate, distinct subset
(Figure 1E). We attribute this distinction to a 5%–7% global
expression difference between our FRDA iPSCs and other
iPSCs/ESCs, whereas an internal variation of only 2%–3%
was observed among other iPSCs/ESCs, a difference that prob-
ably reflects the diseased nature of the FRDA genetic
background. Moreover, functional annotation clustering via the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) of the top differentially expressed genes in FRDA iPSCs
identified gene groups related to mitochondrial function, DNA
repair, and DNA damage response (Table S1). DNA repair also
appeared as a top GO category significantly enriched in our
data set (Table S2), consistent with recent studies on FRDA
patients (Haugen et al., 2010). Additional significant GO
categories were related to cell cycle, protein modification/ubiq-
uitination, lipid metabolism, and carbohydrate biosynthesis, all
of which have been previously associated with altered function
in FRDA patients (Coppola et al., 2006; Haugen et al., 2010).
Global microRNA profiling also shows that the FRDA iPSCs
express many miRNAs associated with pluripotency, but.
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Figure 2. Analysis of GAA,TTC Repeat
Lengths
(A) PCR analysis of FXNGAA,TTC repeat length in
cell lines, patient lymphocytes, and FRDA iPSCs.
DNA length markers are shown in bp. Lanes are
as follows (left to right). Left panel: GM15851
unaffected and GM15850 FRDA lymphoblasts;
FRDA patient D lymphocytes; GM03816 FRDA
fibroblasts; GM03816-derived iPSC lines 1–4; no
DNA control (neg). Middle panel: GM04078
FRDA fibroblasts; GM04078-derived iPSCs
(GM0478-iPS1). Right panel: GM03813 SMA
fibroblasts and two corresponding iPSC lines
(GM03813-iPS1 and -iPS2).
(B) PCR products of the FXN GAA,TTC repeat
region in carrier parents of a FRDA patient. Left
panel (left to right): maternal fibroblast and three
corresponding iPSC lines. Right panel (left to
right): paternal fibroblast and one corresponding
iPSC line.
(C) GAA,TTC repeats at two unrelated genetic loci
in FRDA (GM03816- and GM04078-derived) and
SMA (GM03813-derived) fibroblasts and two iPSC
lines from each. PCR products from GM15851
FRDA lymphoblasts are also shown.
(D) FXN GAA,TTC repeat length PCR measure-
ments over time. Left to right: FRDA fibroblasts
(GM03816), early passage FRDA iPSC (iPS6 early),
and three FRDA iPSC single colony samples at
passage 15 (iPS6 late a-c).
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GAA,TTC Repeat Instability in FRDA iPSCsdistinct differences, again presumably resulting from FRDA
pathogenesis, were also noted (Figures S1G and S1H and
Table S3).GAA,TTC Repeat Expansion in FRDA iPSCs
PCR analysis of the FXNGAA,TTC repeats showed repeat insta-
bility in the iPSC lines (Figure 2A), a phenomenon not seen in
donor fibroblasts (data not shown). PCR products from
unaffected (GM15851) and FRDA (GM15850) lymphoblasts and
an unrelated patient DNA are also shown for comparison. In all
cases, an apparent expansion of both alleles of FRDA iPSCs
was observed (with certain caveats addressed below). PCR
analysis of iPSCs from a second patient (GM04078) similarly
showed repeat expansion (Figure 2A, middle), confirming the
general nature of this observation. In contrast, wild-type FXN
alleles do not change in size in a non-FRDA iPSC control
(Figure 2A; right, GM03813 spinal muscular atrophy iPSCs)
and in non-disease unaffected iPSCs (data not shown). Because
of the allele ambiguity of our PCR assay, shifts in PCR bands
could represent expansion of both alleles or contraction of one
and expansion of the other. Therefore, iPSCs were generated
from carrier parents of a third FRDA patient and subjected to
PCR analysis, showing repeat expansion in both parental patho-
genic alleles (Figure 2B). The wild-type FXN allele, as expected,
did not expand, suggesting a gender-neutral instability in
pathogenic FXN alleles. As in somatic cells, GAA,TTC repeat
expansions at two unrelated genetic loci (2q36, 16 repeats;
4q31.1, 30 repeats) (Rindler et al., 2006) remain unchanged
between our iPSCs and their three corresponding donor fibro-
blasts (Figure 2C), even though these loci are at Alu elements
similar to FXN intron 1. Altogether, the data suggest that changesCelat the FXN gene are a consequence of its particular repeat
expansion (and perhaps its length) and are not a general
phenomenon throughout the human genome. Further, we find
that GAA,TTC repeat lengths in FRDA iPSCs change over time
in culture (Figure 2D).Molecular Basis for Repeat Instability
Previous reports have implicated the MMR enzymes MSH2,
MSH3, and MSH6 in CAG,CTG and CTG,CAG somatic and
intergenerational repeat instability in HD and DM1 (myotonic
dystrophy type I) transgenic mice, respectively (reviewed in
Dion and Wilson, 2009). Other studies have implicated the
oxoguanine-DNA glycosylase OGG1 in somatic instability
(Kovtun et al., 2007). In FRDA iPSCs, mRNA expression analysis
shows large increases in MSH2 compared to donor fibroblasts
(Figure 3A). No differences in MSH3 mRNA, however, were
found, and a small decrease in OGG1 mRNA was noted in the
iPS/ESCs. Western blotting further shows corresponding
increases in MSH2 protein in FRDA iPSCs and H1 ESCs
compared to FRDA fibroblasts (Figure 3B). ChIP assays, at
a resolution of 1 kb, show increased occupancy of MSH2 and
MSH3 downstream of the GAA,TTC repeats in FRDA iPSCs
compared to an unaffected iPSC line but, in contrast, not
1254 bp upstream of the FXN transcriptional start site nor
directly upstream of the GAA,TTC repeats (Figure 3C). No differ-
ences in MSH6 occupancy were found at any of the regions
probed.
To further investigate the role of MSH2 in repeat instability,
lentiviral shRNA constructs were integrated into single colony-
expanded FRDA iPSCs (to limit repeat length heterogeneity)
and assayed for GAA,TTC repeat length (summarized inl Stem Cell 7, 631–637, November 5, 2010 ª2010 Elsevier Inc. 633
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Figure 3. MSH2 Expression and Localiza-
tion in FRDA iPSCs
(A) MSH2, MSH3, and OGG1 mRNA levels in
GM03816 fibroblasts (white), two GM03816 iPSC
lines (iPS4, medium gray; iPS6, dark gray), and
H1 cells (light gray). Levels are normalized to
GAPDH. Errors bars indicate SEM of duplicate
measurements.
(B) Western blot of MSH2 protein. Left to right:
GM03816 fibroblast, two GM03816 iPSC lines
(4 and 6), and H1 hESCs. GAPDH and L13a are
loading controls.
(C) MSH2, MSH3, and MSH6 occupancy on the
FXN gene 1254 bp upstream of the transcriptional
start site (1254), upstream (up GAA) and down-
stream (down GAA) of the GAA,TTC repeat expan-
sion (measured by ChIP). IP recovery is relative to
FXN intron 2 (11482 bp downstream of the tran-
scriptional start site). Error bars indicate SEM of
independent experiments (MSH2, n = 4; MSH3
and MSH6, n = 2).
Cell Stem Cell
GAA,TTC Repeat Instability in FRDA iPSCsFigure 4A). As shown in Figures 4B–4D, stable expression of
MSH2-targeted shRNA achieved relatively high levels of mRNA
and protein knockdown compared to a scrambled shRNA.
Additionally, we verify that MSH2 silencing does not affect
pluripotency (Figure S2A). After eight passages, repeat length
PCR analysis showed thatMSH2 knockdown results in a signifi-
cantly smaller large allele compared to a scrambled shRNA
(Figures 4E–4G). No statistical significance, however, was
observed for the smaller allele based on pooled data, contrary
to the single-point data shown in Figures 4E and 4F. shRNA
silencing of MSH2 in FRDA fibroblasts followed by reprogram-
ming also yielded similar results (Figure S2). Collectively, these
data implicate the involvement of MSH2 in GAA,TTC repeat
instability.DISCUSSION
Our findings demonstrate that triplet repeat instability can
occur in patient-specific iPSCs. Previous studies have analyzed
triplet expansions in disease-specific iPSCs but either did
not compare donor fibroblast repeats or the iPSCs did not
show any changes after reprogramming (Park et al., 2008a;
Urbach et al., 2010). In our case, we observe repeat expansion,
perhaps resembling intergenerational instability as in FRDA
families with one exception. In patient families, only the maternal
pathogenic allele is reported to undergo intergenerational
expansion, whereas the paternal allele usually remains the
same length or can contract (Campuzano et al., 1996; Pianese
et al., 1997). However, we find expansion of both parental
pathogenic alleles in iPSCs. One interpretation for this difference634 Cell Stem Cell 7, 631–637, November 5, 2010 ª2010 Elsevier Incp
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w.is that both alleles undergo the same
cellular changes during in vitro reprog-
ramming as opposed to differential game-
togenesis.
Our finding of MSH2 and possibly
MSH3 as components involved in repeat
expansion is supported by extensiverior studies in various triplet repeat disorders (Dion and Wil-
on, 2009). Early work in Fragile X syndrome models pointed
ward MSH2 as a component responsible for repeat insta-
ility (Kramer et al., 1996). Other studies have shown that
SH2 has a role in both intergenerational and somatic insta-
ility in various HD models (Dragileva et al., 2009), and similar
ndings have been presented in DM1 studies as well (Savouret
t al., 2003). Along similar lines, our present results implicate
SH2 as one of the proteins responsible for GAA,TTC repeat
xpansion. Although we have no direct evidence for an MSH2-
SH3 complex (MutSb), we believe that such a complex is
sponsible in our case, because not only do both MSH2
nd MSH3 localize near pathogenic FXN alleles, but also other
tudies point to the involvement of MutSb as well (Dragileva
t al., 2009; Kim et al., 2008).
Mechanistically, there is also debate over GAA,TTC repeat
stability, and our results are consistent with several models
f FRDA pathogenesis (Ditch et al., 2009; Dragileva et al.,
009; Iyer and Wells, 1999; Shishkin et al., 2009). One model
roposes the formation of an exposed single-stranded DNA
airpin (resembling mismatched DNA) originating from
triple-stranded structure formed by long GAA,TTC repeats,
hich recruits MMR machinery (Wells, 2008). This recruitment
en stabilizes the slipped-stranded intermediates, leading to
peat expansion (reviewed in Mirkin, 2007). Alternatively,
ense/antisense transcription at the FXN locus (De Biase et al.,
009) could allow for transcription-coupled DNA repair and
AA,TTC repeat tract expansion (Ditch et al., 2009). Interest-
gly, transcription-coupled repair has been shown to interact
ith the MutSb complex (Zhao et al., 2009), further supporting
our observations.
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Figure 4. shRNA Silencing of MSH2 in FRDA iPSCs
(A) Diagram of silencing experiment.
(B)MSH2mRNA levels of targeted and scrambled shRNA-expressing FRDA iPSCs.mRNA levels are normalized toGAPDH. Errors bars indicate SEMof duplicate
measurements.
(C) Western blot of MSH2 protein in FRDA iPSCs with scrambled shRNA and targeted shRNA. GAPDH, loading control.
(D) Densitometric analysis of MSH2 protein normalized to GAPDH of previous panel.
(E) PCR of GAA,TTC repeat lengths presilencing (starting iPSC) and eight passages after transduction with no shRNA (no shRNA), scrambled shRNA (scrambled),
and shRNA against MSH2 (targeted). Note: data are from single point data and do not represent pooled data (G).
(F) Signal intensity traces of ethidium-stained agarose gel from (E). Higher gel migration represents smaller PCR bands.
(G) Summary of pooled GAA,TTC repeat length data. See Supplemental Experimental Procedures for quantitation of repeat lengths.
See also Figure S2.
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GAA,TTC Repeat Instability in FRDA iPSCsThere currently exist few model systems in which one can
study GAA,TTC expansions (Al-Mahdawi et al., 2004; Ditch
et al., 2009; Iyer and Wells, 1999; Shishkin et al., 2009).
Despite the fact that a recent report revealed cellular phy-
siological differences between a human disorder and its iPSC
model and urged caution when making associations between
the two (Urbach et al., 2010), these key differences are likely to
be highly context dependent. In our case, we expect that
FRDA iPSCs will provide a valuable, more accessible resource
to study repeat instability mechanisms as well as for differentia-
tion into cell types affected in this human disease (sensory
neurons and cardiomyocytes). Such cellular models will beCeluseful to dissect disease mechanisms and to screen potential
therapeutic agents.EXPERIMENTAL PROCEDURES
Cell Culture
Fibroblasts were grown at 37C and 5% CO2 with 10% FBS (Lonza) in MEM,
2 mM glutamine, 1% NEAA, 20 mM HEPES, and 1% antibiotic-antimycotic
(all from Invitrogen). ESCs/iPSCs were grown at 37C and 5% CO2 on g-irra-
diatedMEFs (GlobalStem) in D-MEM/F12with 20%Knockout SerumReplace-
ment, 1 mM glutamine, 1% NEAA, 15mMHEPES, 0.1 mM b-mercaptoethanol
(all from Invitrogen), 20 ng/mL basic FGF (Stemgent) and were passagedl Stem Cell 7, 631–637, November 5, 2010 ª2010 Elsevier Inc. 635
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GAA,TTC Repeat Instability in FRDA iPSCsmanually every 5 to 7 days. Phoenix cells were grown with 10% FBS (Lonza) in
DMEM, 2 mM glutamine, 20 mM HEPES, and 1% NEAA (all from Invitrogen).
Isolation of Primary Fibroblasts
Dermal explant cultures were established from dispase-treated skin biopsies
on fibronectin underneath a glass coverslip with fibroblast media after
5–7 days. After establishment, primary dermal fibroblasts were cultured as
described above. Biopsies were performed at the University of California,
Los Angeles, under an approved Human Subjects Protocol.
Generation of Viruses
Retroviruses were packaged via Phoenix cells (a gift from the laboratory of
W. Balch) and Fugene6 (Roche). The four reprogramming vectors (Takahashi
et al., 2007; http://www.addgene.org) were packaged individually and
pseudotyped with VSV-G. Lentiviruses were generated by cotransfecting
into 293T cells shRNA constructs with psPAX2 and pMD2.G. Virus-containing
ESC media supernatant was collected throughout 48 hr after transfection (see
Supplemental Experimental Procedures).
Derivation of iPSCs
Previous methods were followed with minor deviations (Park et al., 2008b).
Donor fibroblasts were transduced daily for 3 consecutive days, and 4 to
6 days after the last transduction, cells were replated onto MEFs. Beginning
1 day following, cells were given ESC media daily. Colonies were picked
between 21 and 28 days after transduction.
Lentiviral shRNA Transduction
FRDA iPSCs were subjected to two lentiviral transductions with lentivirus over-
night at 37C with 5 mg/mL polybrene. Cells were then expanded and
subjected to 6 days of puromycin selection (0.4 mg/mL) on DR4 drug-resistant
MEFs (GlobalStem).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton
X-100 (both in PBS). Primary antibodies were incubated at 4C overnight, and
secondary antibodies were incubated at room temperature for one hour
followed by nuclear staining with DAPI (see Supplemental Experimental Proce-
dures for antibodies used).
Nucleic Acid Purification
Total RNA was purified with the RNeasy Plus Mini kit (QIAGEN) according to
the manufacturer. Genomic DNAwas purified by phenol/chloroform extraction
followed by isopropanol precipitation of cell lysates prepared in total cell lysis
buffer (100 mM Tris, 5 mM EDTA, 0.2% SDS, 0.2 M NaCl, 200 mg/mL
proteinase K [pH 8]).
PCR and Quantitative RT-PCR
For GAA,TTC repeat length PCRs, Phusion polymerase (New England Biol-
abs) was used according to the manufacturer. Quantitative RT-PCR analysis
was done with the qScript One-Step SYBRGreen qRT-PCR kit (Quanta Biosci-
ences) according to the manufacturer. All primers for pluripotent markers were
as described (Park et al., 2008b). FXN, MSH2, MSH3, OGG1, and GAPDH
primers are described in Supplemental Experimental Procedures. Analysis
of relative qRT data was performed via the DDCT method (Livak and Schmitt-
gen, 2001). Detection of retroviral transgenes was done by absolute qRT-PCR
with the same kit as above with previously described retrovirus transcript-
specific primers (Takahashi et al., 2007) (see Supplemental Experimental
Procedures).
Western Analysis
Whole cell extracts (in 50 mM Tris [pH 7.4], 150 mM NaCl, 10% glycerol, 0.5%
Triton X-100, protease inhibitor; Roche) were electrophoresed in polyacryl-
amide gels and transferred onto nitrocellulose membranes. Primary antibodies
were incubated overnight, and secondary antibodies were incubated 1 hr at
room temperature. Signals were detected with HRP-conjugated secondary
antibodies and enhanced chemiluminescence (SuperSignal West Pico,
Thermo Scientific) (see Supplemental Experimental Procedures for antibodies
used).636 Cell Stem Cell 7, 631–637, November 5, 2010 ª2010 Elsevier IncChromatin Immunoprecipitation
Cells were crosslinked first with 1.5 mM dithiobis-succinimidyl propionate
(DSP) followed by 1% formaldehyde. Subsequent ChIP procedures were as
described (Herman et al., 2006) with MSH2 antibody (Santa Cruz). Analysis
by qPCR with primers for the FXN promoter, the region upstream of the
GAA,TTC repeats, and the region downstream of the repeats were as
described (Herman et al., 2006). Additional primers are listed in Supplemental
Experimental Procedures.
Microarray Analysis
RNA purification with the MirVana RNA extraction kit (Ambion), labeling with
the TotalPrep kit (Ambion), and hybridization to Illumina HT12 arrays were as
according to the manufacturers.
Data were then filtered, normalized, and hierarchically clustered (Eisen et al.,
1998). Differentially expressed genes compared to a set of unaffected iPSCs
were detected with a false discovery rate-corrected Student’s t test at a signif-
icance level of aFDR < 0.01. Genes with expression level changes greater than
1.75 were then subjected to functional annotation analysis via the Database for
Annotation, Visualization, and Integrated Discovery (DAVID) (Dennis et al.,
2003; Huang da et al., 2009) at a significance level of aFDR < 0.01.
ACCESSION NUMBERS
Microarray data are deposited in the Gene Expression Omnibus as accession
number GSE22651.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and three tables and can be found with this article online at
doi:10.1016/j.stem.2010.09.014.
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